Limitations, agreements, and source contact

A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma · Source last updated 2025-06-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

true

limitations And Caveats

description

This study was terminated prior to completing Part 1 due to business reasons. Study termination was not due to safety concerns.

point Of Contact

email

clinical.trials@ipsen.com

organization

Ipsen

phone

see email

title

Medical Director

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice